⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2121805 | 0.71 | — | — | |
| SCHEMBL65171 | 0.71 | — | — | |
| SCHEMBL29974816 | 0.70 | ALOX15 (0.48) | — | |
| SCHEMBL28486243 | 0.70 | ALOX15 (0.48) | — | |
| Iodomethane SCHEMBL11535813 | 0.67 | ALOX15 (0.44) | — | |
| SCHEMBL27574879 | 0.65 | — | — | |
| Hydrochloric Acid SCHEMBL27396839 | 0.65 | ALOX15 (0.48) | — | |
| SCHEMBL210890 | 0.64 | — | — | |
| SCHEMBL6920526 | 0.64 | ALOX15 (0.41) | — | |
| Hydrochloric Acid SCHEMBL27430428 | 0.64 | ALOX15 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658654-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINES AND PYRAZOLO[1,5-D] [1,2,4]TRIAZINES AS NLRP3 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2025-12-10 | — | — | EP | disclosed |
| CN-112424207-B | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11197857-B2 | Combination therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-11185531-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2021-11-30 | — | — | US | disclosed |
| WO-2021122745-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2021-06-24 | — | — | WO | disclosed |
| US-20210106580-A1 | COMBINATION THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-15 | — | — | US | disclosed |
| WO-2014153090-A1 | PYRAZOLE DERIVATIVES ASPRMT1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014144659-A1 | PYRAZOLE DERIVATIVES AS PRMT1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140221345-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2014100730-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100719-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100734-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| CN-101035791-B | Pyrrolo[1,2-D][1,2-4]triazine as inhibitors of c-JUN N terminal kinases (JNK) and P-38 kinases | NOVARTIS AG | 2010-12-08 | — | — | CN | disclosed |
| EP-1807431-B1 | PYRROLO[1,2-D][1,2-4]TRIAZINE AS INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND P-38 KINASES | NOVARTIS AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| CN-101035791-A | Pyrrolo[1,2-D][1,2-4]triazine as inhibitors of c-JUN N terminal kinases (JNK) and P-38 kinases | NOVARTIS AG (CH) | 2007-09-12 | — | — | CN | disclosed |
| US-5750522-A | COGNITIVE DISORDERS AND TREATMENT OF SENILITY OR MEMORY LOSS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |